


Brazilian Equities: Unveiling Undervalued Opportunities

Brazilian equities performed well in 2022 and 2023, posting annual returns of 14% and 33%, respectively (Exhibit 1). Despite two years of strong performance, the MSCI Brazil Index continues to trade below its pre-COVID level.

Despite the benign economic environment, Brazilian equities appear priced for a gloomy outlook. Against this backdrop, we are invested in companies whose valuations we believe have been unduly punished because of macro and political fears, as well as company-specific controversies.

Exhibit 1
MSCI Brazil vs MSCI Emerging Markets
Index Performance



Source: MSCI
Cumulative performance of the MSCI Brazil Index and MSCI Emerging Markets Index, in USD, base value of 100, from 12/31/2019 - 3/31/2024.


On a forward earnings basis, Brazilian equities are cheaper than they were during the early months of the COVID-19 pandemic, as well as the previous recession of 2014-2016 (Exhibit 2). Meanwhile, the macroeconomic backdrop is more encouraging than in the past. Unemployment is at its lowest level since 2015, and inflation is down to 4% from double-digit percentage points in 2021 and 2022.

We added **Ambev**, the largest brewer in Latin America and Canada, to the portfolio in 2020. At the time, the company faced beer volume declines amid COVID-19 restrictions. Although volumes have bounced back to record highs, Ambev has faced several macroeconomic challenges, including higher input costs due to a weak Brazilian real and commodity cost inflation. More recently, shares fell due to earnings impacted by the devaluation of the Argentine peso, as well as uncertainty surrounding Brazil's new tax regime. Despite potential future tax burdens, we believe the current share price more than discounts any forthcoming changes. Looking ahead, we are optimistic about Ambev's underlying business. We believe the company's premiumization strategy will contribute to further margin expansion, as macroeconomic headwinds abate.

Cosmetics and personal care company **Natura & Co.** is currently executing the integration of its 2020 acquisition of Avon. In 2023, Natura de-levered its balance sheet by first selling the Aesop brand to L'Oréal at an attractive valuation and subsequently selling its UK-based personal care retailer, The Body Shop. Since we added Natura in 2023, the company has begun to integrate Avon's Latin America business with Natura's existing unit. A key focus of management has been better incentivizing Avon agents to sell product rather than recruit other agents, which led to margin compression in the past. The integration has thus far translated to margin expansion driven by increased productivity and cross-selling.

When we added **Banco do Brasil** to the portfolio in 2023, the share price reflected fears that potential intervention by the newly elected government could hinder the company's profitability, as seen during the presidency of Dilma Rousseff. The company currently offers the highest return on equity among Brazil's largest banks. Asset quality has remained strong, and we view the current valuation as compelling.

Exhibit 2
MSCI Brazil Comparison
Price to Earnings over Next Twelve Months



Source: FactSet, MSCI
Chart depicts price to earnings (next twelve months).

FURTHER INFORMATION

This document is intended solely for informational purposes. The views expressed reflect the current views of Pzena Investment Management (“PIM”) as of the date hereof and are subject to change. PIM is a registered investment adviser registered with the United States Securities and Exchange Commission. PIM does not undertake to advise you of any changes in the views expressed herein. There is no guarantee that any projection, forecast, or opinion in this material will be realized. Past performance is not indicative of future results. All investments involve risk, including risk of total loss.

All investments involve risk, including loss of principal. The price of equity securities may rise or fall because of economic or political changes or changes in a company’s financial condition, sometimes rapidly or unpredictably. Investments in foreign securities involve political, economic and currency risks, greater volatility and differences in accounting methods. These risks are greater for investments in Emerging Markets. Investments in small-cap or mid-cap companies involve additional risks such as limited liquidity and greater volatility than larger companies. PIM’s strategies emphasize a “value” style of investing, which targets undervalued companies with characteristics for improved valuations. This style of investing is subject to the risk that the valuations never improve or that returns on “value” securities may not move in tandem with the returns on other styles of investing or the stock market in general.

The specific portfolio securities discussed in this presentation are included for illustrative purposes only and were selected based on their ability to help you better understand our investment process. They were selected from securities in one or more of our strategies and were not selected based on performance. They do not represent all of the securities purchased or sold for our client accounts during any particular period, and it should not be assumed that investments in such securities were or will be profitable. PIM is a discretionary investment manager and does not make “recommendations” to buy or sell any securities. There is no assurance that any securities discussed herein remain in our portfolios at the time you receive this presentation or that securities sold have not been repurchased.

The MSCI information may only be used for internal use, may not be reproduced or disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the MSCI Parties) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages.

This document does not constitute a current or past recommendation, an offer, or solicitation of an offer to purchase any securities or provide investment advisory services and should not be construed as such. The information contained herein is general in nature and does not constitute legal, tax, or investment advice. PIM does not make any warranty, express or implied, as to the information’s accuracy or completeness. Prospective investors are encouraged to consult their own professional advisers as to the implications of making an investment in any securities or investment advisory services.